IP Library Granted Patent US 12662548
Granted Patent B2
US 12662548 · App. 17/960,354 · Granted Jun 23, 2026

Method for treating cancer by administration of antibodies that bind to extracellular region portion of MCEMP1 protein

Inventors: Takayuki Fujita (Kamakura, JP); Fumiyoshi Okano (Kamakura, JP)
Assignee: TORAY INDUSTRIES, INC.
C07K16/30A61K38/00A61K39/39558A61K45/00A61K45/06A61P35/00C07K16/28A61K2039/505C07K2317/732C12N15/09
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12662548
App. No.
17/960,354
Granted
Jun 23, 2026
Kind
B2
Abstract

An object of the present invention is to identify cancer antigen proteins specifically expressed on the surface of cancer cells and to provide a use of antibodies targeting such proteins as therapeutic and/or preventive agents for cancer. The present invention relates to, for example, a pharmaceutical composition for treatment and/or prevention of a cancer, which comprises, as an active ingredient, an antibody or fragment thereof having an immunological reactivity with an MCEMP1 protein having an amino acid sequence shown in any one of the even numbered SEQ ID NOS: 2 to 8 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence, or with a fragment of the MCEMP1 protein comprising 7 or more consecutive amino acids.

Claims (4)

1 . A method of treating a cancer, said method comprising administering a pharmaceutical composition to a subject in need thereof,

wherein said pharmaceutical composition comprises as an active ingredient, a polyclonal antibody specifically binding to a polypeptide consisting of the amino acid sequence of SEQ ID NO: 10 and has an antibody dependent cellular cytotoxicity (ADCC) activity, and

wherein said cancer is a cancer expressing MCEMP1 on the cell surface and said cancer is leukemia or myelodysplastic syndrome.

2 . The method according to claim 1 , further comprising administering a second pharmaceutical composition comprising an antitumor agent to the subject.